Single-Agent Gemcitabine in Heavily Pretreated Ovarian Cancer: Experience from a Canadian Tertiary Centre
Single-agent gemcitabine in heavily pretreated recurrent OC is associated with a median OS of 4 months, and some patients even benefit from further lines of treatment.
Authors
- Gabriel Levin (ORCID: https://orcid.org/0000-0003-1282-5379)
- S. Salvador
- Walter H. Gotlieb (ORCID: https://orcid.org/0000-0001-6227-6369)
- Peter Scalia (ORCID: https://orcid.org/0000-0002-5050-435X)
- Samantha Taylor
- Susie Lau
- Raanan Meyer
Institutions
- Cedars-Sinai Medical Center (US)
- Jewish General Hospital (CA)
Publication Details
- Journal
- Journal of Obstetrics and Gynaecology Canada
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1016/j.jogc.2026.103237
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Israel Cancer Research Fund
- Jewish General Hospital